Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series
Identifieur interne : 002C86 ( Main/Exploration ); précédent : 002C85; suivant : 002C87Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series
Auteurs : David A. Gallagher [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-09-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Chi-Square Distribution, Dopamine, Dopamine (metabolism), Dopamine Agonists (adverse effects), Female, Gambling, Humans, Impulse control disorder, Levodopa (adverse effects), Male, Middle Aged, Nervous system diseases, Odds Ratio, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Pathological gambling, Prospective Studies, Reaction Time (drug effects), Retrospective Studies, Risk Factors, Risk factor, dopamine disregulation, gambling, impulse control disorder.
- MESH :
- chemical , adverse effects : Dopamine Agonists, Levodopa.
- chemical , metabolism : Dopamine.
- drug effects : Reaction Time.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Chi-Square Distribution, Female, Gambling, Humans, Male, Middle Aged, Odds Ratio, Prospective Studies, Retrospective Studies, Risk Factors.
Abstract
Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21611
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B33
- to stream Istex, to step Curation: 000B33
- to stream Istex, to step Checkpoint: 001794
- to stream PubMed, to step Corpus: 002622
- to stream PubMed, to step Curation: 002622
- to stream PubMed, to step Checkpoint: 002658
- to stream Ncbi, to step Merge: 001D17
- to stream Ncbi, to step Curation: 001D17
- to stream Ncbi, to step Checkpoint: 001D17
- to stream Main, to step Merge: 003C08
- to stream PascalFrancis, to step Corpus: 001539
- to stream PascalFrancis, to step Curation: 001782
- to stream PascalFrancis, to step Checkpoint: 001545
- to stream Main, to step Merge: 004135
- to stream Main, to step Curation: 002C86
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title>
<author><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A." last="Gallagher">David A. Gallagher</name>
</author>
<author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name>
</author>
<author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2FFC1B948CA3345C4CE97037E5E84E73D7651463</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21611</idno>
<idno type="url">https://api.istex.fr/document/2FFC1B948CA3345C4CE97037E5E84E73D7651463/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B33</idno>
<idno type="wicri:Area/Istex/Curation">000B33</idno>
<idno type="wicri:Area/Istex/Checkpoint">001794</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Gallagher D:pathological:gambling:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17580327</idno>
<idno type="wicri:Area/PubMed/Corpus">002622</idno>
<idno type="wicri:Area/PubMed/Curation">002622</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002658</idno>
<idno type="wicri:Area/Ncbi/Merge">001D17</idno>
<idno type="wicri:Area/Ncbi/Curation">001D17</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001D17</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Gallagher D:pathological:gambling:in</idno>
<idno type="wicri:Area/Main/Merge">003C08</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0491123</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001539</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001782</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001545</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Gallagher D:pathological:gambling:in</idno>
<idno type="wicri:Area/Main/Merge">004135</idno>
<idno type="wicri:Area/Main/Curation">002C86</idno>
<idno type="wicri:Area/Main/Exploration">002C86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title>
<author><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A." last="Gallagher">David A. Gallagher</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Neurosciences, Royal Free & University College Medical School, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Neurosciences, Royal Free & University College Medical School, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-09-15">2007-09-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1757">1757</biblScope>
<biblScope unit="page" to="1763">1763</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2FFC1B948CA3345C4CE97037E5E84E73D7651463</idno>
<idno type="DOI">10.1002/mds.21611</idno>
<idno type="ArticleID">MDS21611</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Chi-Square Distribution</term>
<term>Dopamine</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Female</term>
<term>Gambling</term>
<term>Humans</term>
<term>Impulse control disorder</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Odds Ratio</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pathological gambling</term>
<term>Prospective Studies</term>
<term>Reaction Time (drug effects)</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Risk factor</term>
<term>dopamine disregulation</term>
<term>gambling</term>
<term>impulse control disorder</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Reaction Time</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Chi-Square Distribution</term>
<term>Female</term>
<term>Gambling</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Odds Ratio</term>
<term>Prospective Studies</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term>
<term>Facteur risque</term>
<term>Jeu pathologique</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Trouble contrôle impulsion</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A." last="Gallagher">David A. Gallagher</name>
</region>
<name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name>
<name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A." last="Gallagher">David A. Gallagher</name>
<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name>
<name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:2FFC1B948CA3345C4CE97037E5E84E73D7651463 |texte= Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |